HC Wainwright Decreases Earnings Estimates for electroCore

electroCore, Inc. (NASDAQ:ECOR) – Analysts at HC Wainwright dropped their Q1 2026 earnings estimates for electroCore in a report released on Thursday, November 6th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.01) per share for the quarter, down from their previous forecast of $0.03. The consensus estimate for electroCore’s current full-year earnings is ($1.49) per share. HC Wainwright also issued estimates for electroCore’s Q2 2026 earnings at $0.04 EPS, Q3 2026 earnings at $0.10 EPS, Q4 2026 earnings at $0.16 EPS, FY2027 earnings at $1.29 EPS, FY2028 earnings at $2.17 EPS and FY2029 earnings at $2.80 EPS.

Several other brokerages have also issued reports on ECOR. Wall Street Zen lowered shares of electroCore from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of electroCore in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $25.50.

electroCore Trading Down 3.9%

ECOR traded down $0.23 during trading on Friday, reaching $5.61. The stock had a trading volume of 137,318 shares, compared to its average volume of 112,349. The company has a market capitalization of $44.88 million, a price-to-earnings ratio of -3.28 and a beta of 0.30. The stock’s 50 day moving average is $5.02 and its two-hundred day moving average is $5.61. electroCore has a one year low of $4.16 and a one year high of $19.49.

electroCore (NASDAQ:ECOR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.07). The firm had revenue of $8.69 million for the quarter, compared to the consensus estimate of $7.84 million. electroCore had a negative net margin of 47.46% and a negative return on equity of 308.23%. electroCore has set its FY 2025 guidance at EPS.

Institutional Trading of electroCore

Several hedge funds have recently bought and sold shares of ECOR. XTX Topco Ltd purchased a new position in shares of electroCore during the first quarter valued at about $90,000. Jump Financial LLC purchased a new stake in shares of electroCore in the first quarter worth about $95,000. Cubist Systematic Strategies LLC bought a new position in electroCore during the first quarter valued at approximately $153,000. Jaffetilchin Investment Partners LLC grew its holdings in electroCore by 26.7% during the 2nd quarter. Jaffetilchin Investment Partners LLC now owns 41,783 shares of the company’s stock valued at $221,000 after buying an additional 8,800 shares in the last quarter. Finally, Jane Street Group LLC increased its stake in electroCore by 114.4% in the 1st quarter. Jane Street Group LLC now owns 36,726 shares of the company’s stock worth $246,000 after acquiring an additional 19,599 shares during the last quarter. Institutional investors own 26.74% of the company’s stock.

Insider Buying and Selling at electroCore

In related news, Director Thomas J. Errico acquired 15,000 shares of the stock in a transaction that occurred on Monday, August 11th. The shares were bought at an average price of $4.47 per share, for a total transaction of $67,050.00. Following the completion of the transaction, the director directly owned 281,401 shares in the company, valued at approximately $1,257,862.47. This trade represents a 5.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.80% of the stock is owned by insiders.

About electroCore

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.